Adagio Medical — Third Quarter 2026 Earnings Summary
Financial Performance:
- Reported revenue of $0 for the three months ended September 30, 2026, compared to $0 in the same period in 2025.
- Cost of revenue was $0 for Q3 2026, a decrease from $31,000 in Q3 2025, primarily due to the pause in commercial activity in Europe.
- Research and development expenses were $1.8 million for Q3 2026, down from $2.8 million in Q3 2025, driven by lower clinical trial and operational costs.
- Selling, general and administrative expenses were $2.6 million for Q3 2026, down from $2.9 million in Q3 2025, resulting from lower professional services and regulatory reporting expenses, partially offset by higher payroll.
- Net income was $17.8 million ($2.40 per basic share) for Q3 2026, compared to a net loss of $10.1 million ($(19.73) per basic share) in Q3 2025.
- The Q3 2026 net income was primarily driven by a $23.0 million noncash gain related to the change in fair value of the Company's 13% Senior Secured Convertible Notes.
- Diluted net loss per share for Q3 2026 was $(5.13), reflecting the exclusion of the noncash fair-value gain associated with the Notes.
- Cash and cash equivalents were $3.1 million as of September 30, 2026, down from $17.1 million as of December 31, 2025.
- Total assets were $29.9 million as of September 30, 2026, compared to $43.3 million as of December 31, 2025.
- Total liabilities were $11.5 million as of September 30, 2026, compared to $30.9 million as of December 31, 2025.
- Total stockholder's equity was $18.4 million as of September 30, 2026, compared to $12.4 million as of December 31, 2025.
Business Segments and Product Lines:
- The Company's vCLAS Ventricular Ablation System is CE Marked and commercially available in Europe and select geographies but remains limited to investigational use in the United States.
- The Company submitted results of the FULCRUM-VT pivotal study to the FDA in May 2026 to support its Premarket Approval (PMA) application for the vCLAS Ventricular Ablation System.
- The PMA application for the vCLAS Ventricular Ablation System remains under FDA review.
- The Company initiated the vCLAS Ultra Investigational Device Exemption (IDE) sub-study to evaluate the next-generation vCLAS Ultra catheter for Ventricular Tachycardia.
- The first patient was treated in the IDE sub-study at Banner – University Medical Center Phoenix, with enrollment expanding across multiple sites.
- A total of 22 patients were treated with the vCLAS Ultra System in the United States and Canada during the quarter, including 19 patients in the FULCRUM-VT IDE sub-study and 3 compassionate use cases.
- The ULTA platform was featured in four podium presentations at the VT Symposium 2026, highlighting clinical experience, preclinical research, and insights from FULCRUM-VT.
- Physician interest focused on the next-generation vCLAS Ultra catheter's handling, streamlined workflow, and ability to create time-efficient deep wide footprint lesions.
Management Commentary and Tone:
- CEO Todd Usen stated the third quarter was defined by progress in clinical and regulatory programs forming the foundation for the Company's value and ULTA platform.
- Management noted the alignment of the cost structure around prioritized programs while the Board reviews strategic alternatives.
- The tone emphasized maximizing shareholder value and the clinical differentiation of the all-endocardial approach to VT.
Other Key Points:
- The Board of Directors initiated a formal process to explore strategic alternatives focused on maximizing shareholder value.
- On November 6, 2026, the Company effected a one-for-thirty (1-for-30) reverse stock split to regain compliance with Nasdaq's Minimum Bid Price Requirement.
- All share and per-share amounts in the press release have been retroactively adjusted to reflect the reverse stock split.
- The Company's common stock began trading on a split-adjusted basis on November 9, 2026.
- The FULCRUM-VT trial has fully enrolled 209 patients with structural heart disease indicated for catheter ablation of drug-refractory VT.
- The FDA granted IDE approval to expand the FULCRUM-VT trial to evaluate the safety and effectiveness of the next-generation vCLAS Ultra catheter.
- Certain outstanding warrants and other potentially dilutive securities were excluded from the diluted earnings per share calculation as their inclusion would have been anti-dilutive.
- Company
- ADAGIO MEDICAL HOLDINGS INC
- Sector
- Healthcare
- Industry
- Medical Devices